So, to wake up this morning to "CEO: 5000-percent drug price hike "not excessive at all",
was kind of a slap in the face. Here I am trying to gently and tactfully explain the cost of drug and vaccine R&D, while this guy tweets his flippant responses to detractors without restrain and at one point in a vulgar way, way worse than a rebellious teenager.
Here are some key points and facts for those interested.
- Daraprim (Pyrimethamine) is a prophylactic antimalarial agent against Plasmodium falciparum and in the treatment of toxoplasmosis.
- Toxoplasma gondii can be transmitted to humans by eating undercooked pork or lamb that contains this protozoa, or through ingestion of contaminated vegetables. Usually individuals don't show symptoms unless one is immunocompromised - those with severely weakened immune systems.
- As can be expected, these parasites usually infect already HIV-infected patients. Yes, these are opportunistic little bastards.
- In general, the drug development process is complex, lengthy, risky and expensive.
- It takes about 10-12 years for a drug to travel the lab bench (research) to patient's bed. After drug discovery, which means sorting through tens of thousands of candidate compounds for a few active ones, the lead compound has to be optimized, get approved for trials, go through Phase I, II, III (and sometimes IV) trials before it can be registered and manufactured in large scale.
- Neglected and rare diseases (diseases that primarily affect the developing world) are given less R&D funding and attention because either a smaller part of the population is affected (smaller market) or there's smaller financial gain from developing countries and considered non-commercial.
- Very few big pharma companies are interested in investing resources for reasons mentioned above.
- Furthermore, many multinational Super Companies have downsized, and the first budget they cut is the less profitable infectious disease division.
- Small companies, like Turing, often focus on technologies or niche markets.
- The wheel of drug discovery need to keep churning as pathogens evolve with increasing drug-resistance.
So, going back to the Daraprim case, I think it is reasonable that the drug cost be increased to support the cost of R&D. What gets me though is the amount of price hike. 5000% increase. Really. Can you at least break that down for us? If you currently have 25 scientists, and plan to double that, it would justify a 100% hike from $14 to $28, don't you? Triple it even, if needed for return of investment (ROI). Let's be honest, the guy is clearly trying to recoup the cost of the start-up, but what else? I would really like some transparency here on how they came to that figure ($750). One thing to note is that this price hike is egregious, and does not represent the usual drug price increases. Was market research even conducted in this case? Plus, no one should really be flippant in addressing a situation like this. Ethical and humanitarian reasonings should apply.
It really saddens me that R&D researchers could take the blow for this, and will further bring the reputation of drug industry down the sink - inclusive of the not-for-profit ones. This kind of increase reflects the fault in an unregulated drug market. And I for one cannot wait to hear our the plans that our political candidates plan to unveil to address this.
As a former synthetic chemist, I suddenly had the itch to go back and synthesize that damn pyrethamine. (I'll atone for my language later.) This move should be a wake up call, and the only incentive one would need to put their hard efforts in neglected diseases.
This news make me really sick to my stomach. Oh wait - I hope it's not Toxoplasma, because I sure as heck can't afford Daraprim's price tag.
UPDATE: What do you know, social media has a voice after all! It appears that the price hike will be rolled back. How low? We'll have to stay tuned for that. With all eyes on the company and the drug, and scrutiny from social media users, the government and big pharma, Turing better be doing their research.